Status:
SUSPENDED
Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia
Lead Sponsor:
Hamamatsu University
Conditions:
Schizophrenia
Negative Symptoms
Eligibility:
All Genders
18-50 years
Brief Summary
Dopamine has been closely associated with prefrontal function. The hypothesis that a lower dopaminergic activity is associated with negative symptoms and cognitive dysfunction observed in the patients...
Eligibility Criteria
Inclusion
- Patients
- Were age 18-50 years, met the DSM-IV criteria for schizophrenia
- Were treated with a stable dose of risperidone, raging 2 to 6mg, for more than 8 weeks
- Had a score ≥15 on negative subscale items in Positive and Negative Syndrome Scale (PANSS)
- Had a minimum period of symptom stability, defined as no more than 20% change on consecutive ratings on PANSS for at lease 4 weeks
Exclusion
- Had a history of medical condition or drug treatment that may have affected cognitive performance
- Had a history of other psychiatric disorders
Key Trial Info
Start Date :
March 1 2003
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00197483
Start Date
March 1 2003
Last Update
September 20 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamamatsu University Hospital
Hamamatsu, Shizuoka, Japan, 431-3192